Please log in
You must be logged in to send the contact request.
Manage stand orders
Select Option
Fluxergy, Inc.
13766, Alton Parkway Suite 150,
92618
Irvine, CA
USA
USA
Submit your contact details
Provide your contact details to the exhibitor. Optionally, you may also add a personal message.
Your name, phone number, and e-mail address are subject to the submission of personal data. Messe Düsseldorf GmbH expressly points out that for a data transmission into third countries, for which no adequacy decision of the EU-commission is on hand certifying an adequate level of protection of personal data, it is not ensured that there are appropriate safeguards for the protection of personal data on hand.
An error has occurred
Please check your internet connection or try again later.
Message has been sent
Your message to the exhibitor was sent successfully.
Media files
Contact
Dr. Ali Tinazli
Chief Commercial Officer
Visit us
16.11.2020
Topic
all-day
Fluxergy COVID-19 Sample-to-Answer RT-PCR Test*
The Fluxergy Analyzer system is a testing platform designed for multiplex, multimodal assays*. Fluxergy’s CoVID-19-Sample-to-Answer-RT-PCR test, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to identify the
SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests
with patient samples by researchers at University of California San Diego (UCSD).
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests
with patient samples by researchers at University of California San Diego (UCSD).
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
all-day
How the Coronavirus SARS-CoV-2 Exposes the Flaws of Current Health Testing
The rapid spread of COVID-19, which has the potential to become a once-in-a-century pandemic,
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
17.11.2020
Topic
all-day
Fluxergy COVID-19 Sample-to-Answer RT-PCR Test*
The Fluxergy Analyzer system is a testing platform designed for multiplex, multimodal assays*. Fluxergy’s CoVID-19-Sample-to-Answer-RT-PCR test, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to identify the
SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests
with patient samples by researchers at University of California San Diego (UCSD).
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests
with patient samples by researchers at University of California San Diego (UCSD).
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
all-day
How the Coronavirus SARS-CoV-2 Exposes the Flaws of Current Health Testing
The rapid spread of COVID-19, which has the potential to become a once-in-a-century pandemic,
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
18.11.2020
Topic
all-day
Fluxergy COVID-19 Sample-to-Answer RT-PCR Test*
The Fluxergy Analyzer system is a testing platform designed for multiplex, multimodal assays*. Fluxergy’s CoVID-19-Sample-to-Answer-RT-PCR test, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to identify the
SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests
with patient samples by researchers at University of California San Diego (UCSD).
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests
with patient samples by researchers at University of California San Diego (UCSD).
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
all-day
How the Coronavirus SARS-CoV-2 Exposes the Flaws of Current Health Testing
The rapid spread of COVID-19, which has the potential to become a once-in-a-century pandemic,
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
19.11.2020
Topic
all-day
Fluxergy COVID-19 Sample-to-Answer RT-PCR Test*
The Fluxergy Analyzer system is a testing platform designed for multiplex, multimodal assays*. Fluxergy’s CoVID-19-Sample-to-Answer-RT-PCR test, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to identify the
SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests
with patient samples by researchers at University of California San Diego (UCSD).
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests
with patient samples by researchers at University of California San Diego (UCSD).
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
all-day
How the Coronavirus SARS-CoV-2 Exposes the Flaws of Current Health Testing
The rapid spread of COVID-19, which has the potential to become a once-in-a-century pandemic,
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Our range of products
Product categories
- 03 Diagnostic tests
- 03.01 Clinical chemistry
- 03.01.03 Urinalysis equipment and systems
Urinalysis equipment and systems
- 03 Diagnostic tests
- 03.01 Clinical chemistry
- 03.01.04 Rapid tests in clinical chemistry
Rapid tests in clinical chemistry
- 03 Diagnostic tests
- 03.02 Immunochemistry testing, immunology testing
- 03.02.01 Immuno assay testing
Immuno assay testing
- 03 Diagnostic tests
- 03.02 Immunochemistry testing, immunology testing
- 03.02.02 Diagnostic rapid tests
Diagnostic rapid tests
- 03 Diagnostic tests
- 03.03 Haematology / histology / cytology testing
- 03.03.04 Other haematology / histology / cytology testing
Other haematology / histology / cytology testing
- 03 Diagnostic tests
- 03.04 Microbiology testing
- 03.04.03 Rapid tests in microbiology
Rapid tests in microbiology
- 03 Diagnostic tests
- 03.05 Infectious immunology testing
- 03.05.02 Microbiological diagnosis, virology, equipment and systems for
Microbiological diagnosis, virology, equipment and systems for
- 03 Diagnostic tests
- 03.06 Genetic testing, molecular diagnostics
- 03.06.01 DNA testing
- 03 Diagnostic tests
- 03.06 Genetic testing, molecular diagnostics
- 03.06.02 Molecular biomarkers
Molecular biomarkers
- 03 Diagnostic tests
- 03.06 Genetic testing, molecular diagnostics
- 03.06.03 Polymerase chain reaction (PCR)
Polymerase chain reaction (PCR)
- 06 Information and communication technology
- 06.02 mHealth, mobile IT, wireless technologies (Bluetooth, WI-FI)
mHealth, mobile IT, wireless technologies (Bluetooth, WI-FI)
- 06 Information and communication technology
- 06.04 eHealth, telemedicine / telematics / telemetry
eHealth, telemedicine / telematics / telemetry
Our products
Product category: Diagnostic rapid tests, Microbiological diagnosis, virology, equipment and systems for, Polymerase chain reaction (PCR), DNA testing, Molecular biomarkers, mHealth, mobile IT, wireless technologies (Bluetooth, WI-FI), eHealth, telemedicine / telematics / telemetry
Fluxergy COVID-19 Sample-to-Answer RT-PCR Test*
The Fluxergy Analyzer system is a testing platform designed for multiplex, multimodal assays*. Fluxergy’s CoVID-19-Sample-to-Answer-RT-PCR test, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to identify the
SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests
with patient samples by researchers at University of California San Diego (UCSD).
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities
are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future evenets could differ materially from those anticipated in such statements.
SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests
with patient samples by researchers at University of California San Diego (UCSD).
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities
are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future evenets could differ materially from those anticipated in such statements.
Product category: Polymerase chain reaction (PCR), Urinalysis equipment and systems, Rapid tests in clinical chemistry, Immuno assay testing, Diagnostic rapid tests, Other haematology / histology / cytology testing, Rapid tests in microbiology, Microbiological diagnosis, virology, equipment and systems for, DNA testing, Molecular biomarkers, mHealth, mobile IT, wireless technologies (Bluetooth, WI-FI), eHealth, telemedicine / telematics / telemetry
Fluxergy Analyzer*
Our core device, the Fluxergy Analyzer, is a highly-integrated sensor system along with our sophisticated analysis algorithms. The Fluxergy Analyzer can be used for laboratory analyses such as PCR, ELISA, ISE, and cytometry-based assays.
Ruggedized Exterior Casing
The Fluxergy Analyzer features a smooth monocoque casing that is both lightweight and robust.
Active Cooling System
The active cooling system allows the Fluxergy Analyzer to rapidly manipulate the subjected sample to significantly decrease test times.
Quick Battery Hookup
Whether you are in a resource-limited setting or at a high-tech laboratory, the Fluxergy Analyzer can always have power. Simply hook up a compatible battery pack and realize the portability of the Fluxergy Analyzer system.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities
are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Ruggedized Exterior Casing
The Fluxergy Analyzer features a smooth monocoque casing that is both lightweight and robust.
Active Cooling System
The active cooling system allows the Fluxergy Analyzer to rapidly manipulate the subjected sample to significantly decrease test times.
Quick Battery Hookup
Whether you are in a resource-limited setting or at a high-tech laboratory, the Fluxergy Analyzer can always have power. Simply hook up a compatible battery pack and realize the portability of the Fluxergy Analyzer system.
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities
are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Company news
Date
Topic
Download
Nov 13, 2020
Video: Tej Patel: Why We Need Multimodal Testing
Nov 13, 2020
Video: How Fluxergy Could Disrupt and Transform the Healthcare Industry
About us
Company details
Fluxergy, founded in 2013, seeks to provide a portable, easy-to-use sample-to-answer platform that enables clinicians to cost-effectively conduct a wide range of sophisticated multiplex and multimodal in vitro diagnostic tests (different types of tests all at once, up to 30 targets) at the point-of-care.
The Fluxergy Diagnostic Testing System consists of The Fluxergy Card, a single-use “lab-on-chip” consumable test cartridge; the Fluxergy Analyzer, which conducts the testing process, and; the FluxergyWorks software, used by the clinician/operator to review and interpret the test data. The Fluxergy Cards are designed to be very cost-effective and scalable, using proprietary printed circuit board (PCB) manufacturing and microfluidics technologies. FluxergyWorks enables organizations to link together via the Cloud as many as 256 Fluxergy Analyzers for centralized data reporting.
Please visit fluxergy.com for more information.
Contact: Dr. Ali Tinazli, atinazli@fluxergy.com
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this video regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
The Fluxergy Diagnostic Testing System consists of The Fluxergy Card, a single-use “lab-on-chip” consumable test cartridge; the Fluxergy Analyzer, which conducts the testing process, and; the FluxergyWorks software, used by the clinician/operator to review and interpret the test data. The Fluxergy Cards are designed to be very cost-effective and scalable, using proprietary printed circuit board (PCB) manufacturing and microfluidics technologies. FluxergyWorks enables organizations to link together via the Cloud as many as 256 Fluxergy Analyzers for centralized data reporting.
Please visit fluxergy.com for more information.
Contact: Dr. Ali Tinazli, atinazli@fluxergy.com
*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this video regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Company data
Number of employees50-99
Foundation2013
Area of business- Imaging and diagnostics / medical equipment & devices
- Laboratory equipment
- Diagnostics